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LETTERS TO THE EDITOR 
Modulation of alloreactivity in transplant 
recipients by phenotypic manipulation of donor 
endothelium 
To the Editor: 
I read with interest he report by Quigley and associates 
(J THORAC CARDIOVASC SURG 1995;109:905-9) of their 
observations concerning rat cardiac allograft prolongation 
by pretreatment of the donor with intravascular injection 
of recipient ype endothelial cells. Clearly such a simple 
approach could have direct clinical application. What is 
less clear is the interpretation of this interesting phenom- 
enon. The title of the report suggests two things: (1) that 
the alloreactivity of the recipient has been altered and (2) 
that phenotypic manipulation of the donor endothelium 
itself has occurred. Unfortunately, there seems to be little 
evidence of the latter, and because of the lack of appro- 
priate controls the article offers inadequate information 
with respect o the former. 
Evidence is presented that recipient-type ndothelial 
cells have "seeded the graft." An argument ispresented in 
the discussion segment that these endothelial cells "pro- 
liferate in the allograft vascular tree"; however, there is no 
direct evidence of such proliferation provided. Further- 
more, although the authors uggest that immunomodula- 
tion is occurring by "either masking the expression of the 
class II MHC [major histocompatibility complex] mole- 
cules or causing up-regulation or down-regulation of 
MHC or cell adhesion genes (or both) in the donor 
endothelium," they offer no immunohistochemical evi- 
dence of any of these potential mechanisms. The breadth 
of this hypothetical mechanism is such that it is of limited 
usefulness in the interpretation of the data. Furthermore, 
no direct evidence is provided that the donor endothelium 
is an any way phenotypically modified. Again, an immu- 
nohistochemical study demonstrating staining of endothe- 
lial cells with markers identifying the cells as donor in 
origin counterstained to demonstrate the hypothesized 
phenotypic modification would be more helpful. This is 
not to say that phenotypic modification did not occur. We 
simply do not know. 
The studies presented leave us equally uninformed 
regarding the effect of this donor graft pretreatment on 
alloreactivity. Skin graft data are presented emonstrating 
(remarkably) neither prolongation or accelerated rejec- 
tion of donor-specific skin grafts in animals bearing 
treated grafts. That is, there is no effect on these grafts as 
compared with those of animals treated with subtherapeu- 
tic cyclosporine. Unfortunately, inasmuch as the hypoth- 
esis of this study is stated to be the effect of manipulation 
of allograft endothelium by means of recipient-type endo- 
thelial seeding, an additional crucial control would be an 
animal given an unmodified heart graft. Rejection of the 
skin graft does not cause rejection of the heart graft. It is 
as if the recipient is immunologically blind to the modified 
graft, a very intriguing observation! Unfortunately, this 
does not quite square with the mixed lymphocyte culture 
data presented, which actually demonstrate some evi- 
dence of sensitization to donor-type cells. Although the 
stimulation index is globally reduced (most likely as a 
result of cyclosporine immunosuppression, as acknowl- 
edged by the authors), the peak in the point of maximal 
proliferation is advanced from day 8 to day 6 as compared 
with proliferation in untreated animals. Again, a crucial 
control would be comparison with an animal receiving an 
unmodified graft. This control would address the question 
of whether the alloreactivity of the recipients has been 
modified by pretreatment of the donor graft. 
The studies described by Quigley and associates are an 
exciting inverse of the classic enhancement experiments 
also performed with vascularized grafts in rats. In these, 
injection of donor-type cells into the host produced graft 
prolongation that appeared to be due to a local phenom- 
enon that was transferrable with the graft itself on retrans- 
plantation. Retransplantation f these heart grafts into 
naive recipients might help to answer the question of 
whether some sort of local suppression is active. If so, 
would the authors consider this a form of local tolerance? 
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Reply to the Editor: 
My colleagues and I appreciate the comments by 
Dr. Sundt regarding our article "Modulation of Atloreac- 
tivity in Transplant Recipients by Phenotypic Manipula- 
tion of Donor Endothelium." We must emphasize that 
these data represent a "pilot" project only and that the 
mechanism of the observed phenomenon is yet to be 
established. As outlined, our conclusions are hypotheses 
presently under investigation. 
When the study was initially designed, we realized that 
the most definitive trafficking study would include trans- 
fection of the host endothelial cells with a vector that is 
replication defective and that contains /3-galactosidase 
and neomycin-resistant genes. Incubation of transplant 
sections with X-gal chromagen would demonstrate blue 
chromatin if transfected cells were present. At the time, 
our laboratory did not have such technology (Nabel et al. 
Science 1990;244:1342-4). tn this pilot project, we substi- 
tuted the fluorescent cell label for this sophisticated 
technique. Although this latter method is somewhat prim- 
itive, we were satisfied that with simple fluorescent light 
microscopy, these labeled cells remained in the vessel 
wall, because we could easily differentiate blood vessels 
from the myocardial parenchyma. One would have ex- 
pected this "tag" to be located in the extravascular space 
(in association with macrophages) if the labeled cells were 
not viable. We could not demonstrate any PKH 26 dye 
1773 
